ライフサイエンスコーパス: chronic hepatitis B

1 shed nucleotide analogue in the treatment of chronic hepatitis B.

2 offer a potential new treatment strategy for chronic hepatitis B.

3 on, but limited data exist for patients with chronic hepatitis B.

4 l vectors, may be useful in the treatment of chronic hepatitis B.

5 after liver biopsy in a 10-year-old boy with chronic hepatitis B.

6 nagement of patients with HBeAg-seronegative chronic hepatitis B.

7 n therapies in immune-tolerant patients with chronic hepatitis B.

8 ay be a good alternative to TDF for treating chronic hepatitis B.

9 h potential for the therapeutic treatment of chronic hepatitis B.

10 tudy of immunotherapeutic approaches against chronic hepatitis B.

11 antiviral therapeutics for the treatment of chronic hepatitis B.

12 sign of curative antiviral therapies against chronic hepatitis B.

13 e to PEG-IFN in patients with HBeAg-positive chronic hepatitis B.

14 ermines the success of long-term therapy for chronic hepatitis B.

15 tion of treatment duration and cessation for chronic hepatitis B.

16 on (IFN-alpha) is an approved medication for chronic hepatitis B.

17 n estimated 10% of HIV-infected persons have chronic hepatitis B.

18 ents have been approved for the treatment of chronic hepatitis B.

19 llular carcinoma among certain patients with chronic hepatitis B.

20 as first-line therapy for all patients with chronic hepatitis B.

21 n in defining optimal means of management of chronic hepatitis B.

22 contribute to the therapeutic management of chronic hepatitis B.

23 Six approved therapies are available for chronic hepatitis B.

24 and foreseeable therapeutic developments in chronic hepatitis B.

25 diseases, which may open a new venue to cure chronic hepatitis B.

26 foreign-born African Americans (FBAAs) with chronic hepatitis B.

27 on of antiviral therapeutics for the cure of chronic hepatitis B.

28 f serum samples from patients with acute and chronic hepatitis B.

29 of off-NA VR in patients with HBeAg-negative chronic hepatitis B.

30 patients with hepatitis B e antigen-negative chronic hepatitis B.

31 st controversial topics in the management of chronic hepatitis B.

32 Chronic hepatitis B affects over 300 million people who

33 ent hepatitis B recurrence for patients with chronic hepatitis B after liver transplantation.

34 s to achieve a 90% reduction in new cases of chronic hepatitis B and C and a 65% reduction in mortali

35 specific immune cells in the pathogenesis of chronic hepatitis B and C and discusses recent findings

36 Approximately 40% of chronic hepatitis B and C patients are susceptible to or

37 We identified chronic hepatitis B and C patients with healthcare utili

38 Chronic hepatitis B and C virus infections are major cau

39 idity and mortality due to co-infection with chronic hepatitis B and C viruses.

40 r reimbursed treatment) received therapy for chronic hepatitis B and C, respectively, by 2011.

41 in serum samples from patients with acute vs chronic hepatitis B and controls.

42 Chronic hepatitis B and D infections are major causes of

43 ing uninfected pregnant women, patients with chronic hepatitis B and D virus (HBV/HDV) infection, and

44 r carcinoma (HCC) and current treatments for chronic hepatitis B and HCC are suboptimal.

45 global burden of viral hepatitis, especially chronic hepatitis B and hepatitis C virus infections.

46 o reveal the molecular basis associated with chronic hepatitis B and IFN-alpha (IFNalpha) treatment r

47 undetectability are important milestones of chronic hepatitis B and major treatment endpoints of ant

48 gene that associated most significantly with chronic hepatitis B and outcomes to HBV infection in Asi

49 atitis B virus (HBV), the causative agent of chronic hepatitis B and prototypic hepadnavirus, is a sm

50 atobiliary cystadenocarcinoma in female with chronic hepatitis B and repeated hepatolithiasis.

51 lay an important role in staging and grading chronic hepatitis B and should be more widely used in as

52 elated to treatment outcome in patients with chronic hepatitis B are currently unknown.

53 er cancer associated with childhood-acquired chronic hepatitis B are leading causes of death among ad

54 ee of fibrosis, end-stage liver disease, and chronic hepatitis B at baseline (n = 485) were included.

55 pical hepatitis B e antigen (HBeAg) positive chronic hepatitis B, but a lesser proportion of those wi

56 own to reduce the rate of drug resistance in chronic hepatitis B, but only when drugs with a low barr

57 ents with acute hepatitis B and C as well as chronic hepatitis B, C, and delta (D) patients were stud

58 Chronic hepatitis B carries a higher risk of death from

59 HBV genotype distribution between acute and chronic hepatitis B cases and the rapid decline in hepat

60 It is not known whether chronic hepatitis B (CH-B) or chronic hepatitis C (CH-C)

61 sponse to antiviral therapy in patients with chronic hepatitis B (CHB) , and to assess if these miRNA

62 129 with chronic hepatitis C (CHC), 555 with chronic hepatitis B (CHB) and 488 with non-alcoholic fat

63 sis is a common histopathological feature of chronic hepatitis B (CHB) and has been associated with s

64 huck is used as an animal model for studying chronic hepatitis B (CHB) and HBV-associated hepatocellu

65 elopments in the evaluation and treatment of chronic hepatitis B (CHB) based on articles published be

66 the recent developments in the management of chronic hepatitis B (CHB) based on the articles publishe

67 elated liver cirrhosis and 115 patients with chronic hepatitis B (CHB) before and after 48 weeks of a

68 of oral nucleos(t)ide analogs (NAs) to treat chronic hepatitis B (CHB) brings about safety data in a

69 Inactive chronic hepatitis B (CHB) carriers make up the largest g

70 Chronic hepatitis B (CHB) exhibits a variety of clinical

71 Chronic hepatitis B (CHB) has become a treatable and con

72 M) treatment has been commonly used to treat Chronic Hepatitis B (CHB) in Asian countries based on TC

73 Estimates of the prevalence of chronic hepatitis B (CHB) in the United States differ si

74 eotide analogs approved for the treatment of chronic hepatitis B (CHB) including three agents approve

75 Chronic hepatitis B (CHB) infection acquired perinatally

76 The natural course of chronic hepatitis B (CHB) infection and treatment respon

77 s B surface antigen (HBsAg) seroclearance in chronic hepatitis B (CHB) infection are unknown.

78 Chronic hepatitis B (CHB) infection is the major cause o

79 has been difficult to study in patients with chronic hepatitis B (CHB) infection.

80 r cirrhosis and/or hepatocellular carcinoma, chronic hepatitis B (CHB) is a major health problem.

81 Chronic hepatitis B (CHB) is characterized by hepatic in

82 elationship between vitamin D metabolism and chronic hepatitis B (CHB) is less well characterized.

83 Chronic hepatitis B (CHB) is major global health problem

84 ong-term nucleoside analogue (NA) therapy in chronic hepatitis B (CHB) is undetermined.

85 -cure hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) is unknown.

86 y of interferon alpha (IFNalpha) therapy for chronic hepatitis B (CHB) patients is about 40% and ofte

87 that the responses to IFN-alpha treatment of chronic hepatitis B (CHB) patients is influenced by IFN-

88 to test this stopping rule in HBeAg-negative chronic hepatitis B (CHB) patients treated with entecavi

89 ls and methods to substitute liver biopsy in chronic hepatitis B (CHB) patients were investigated but

90 rial, hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients with compensated live

91 Th9 and Th17 cells were quantified in chronic hepatitis B (CHB) patients with hepatic fibrosis

92 patitis B virus (HBV) genome often emerge in chronic hepatitis B (CHB) patients.

93 V DNA levels for inactive carrier status and chronic hepatitis B (CHB) progression in a community-bas

94 and their time relationship in patients with chronic hepatitis B (CHB) remain unclear.

95 nt of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) results in HBeAg loss in 30% o

96 We review here new developments in chronic hepatitis B (CHB) treatment, based on review of

97 Patients with chronic hepatitis B (CHB) usually acquire the virus peri

98 Globally, one third of prevalent chronic hepatitis B (CHB) virus infection (HBV) occurred

99 The clinical role of STAT3 in chronic hepatitis B (CHB) was also investigated.

100 ated the antiviral response of patients with chronic hepatitis B (CHB) who had baseline high viral lo

101 Treatment of patients with chronic hepatitis B (CHB) with nucleos(t)ide analogues (

102 ng nucleos(t)ide analogue (NUC) treatment of chronic hepatitis B (CHB), but not all VBTs are due to d

103 sponse to peginterferon (PEG-IFN) therapy in chronic hepatitis B (CHB), but previously proposed predi

104 In chronic hepatitis B (CHB), failure to control hepatitis

105 The incidences of chronic hepatitis B (CHB), Hepatitis B virus (HBV)-assoc

106 ti-HBsAg antibodies (HBsAb) in patients with chronic hepatitis B (CHB), often in the absence of amino

107 t)ide analog (NA) treatment in patients with chronic hepatitis B (CHB).

108 pecific T cells are functionally impaired in chronic hepatitis B (CHB).

109 st well-controlled viruses, in patients with chronic hepatitis B (CHB).

110 s B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB).

111 efficacy of tenofovir DF in adolescents with chronic hepatitis B (CHB).

112 viral activity in treatment of patients with chronic hepatitis B (CHB).

113 voxil (ADV) in children and adolescents with chronic hepatitis B (CHB).

114 with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB).

115 ctive factors against disease progression in chronic hepatitis B (CHB).

116 ndependent risk factor of liver cirrhosis in chronic hepatitis B (CHB).

117 tory responses can define clinical stages of chronic hepatitis B (CHB).

118 role in control of viral replication during chronic hepatitis B (cHBV) infection, but little is know

119 Chronic hepatitis B continues to be a major cause of end

120 The management of chronic hepatitis B currently rests with long-term thera

121 ed that the current treatment guidelines for chronic hepatitis B excluded patients who developed seri

122 Adults with chronic hepatitis B had increased risk for poorer health

123 Many adults with chronic hepatitis B had low absolute risks of clinical o

124 TDF-treated patients with chronic hepatitis B have reduced bone mineral density, b

125 Patients with chronic hepatitis B (HBV DNA load, >17 000 IU/mL) were t

126 d that lack of knowledge and awareness about chronic hepatitis B (HBV) and C virus (HCV) infections a

127 in clinical evaluation for the treatment of chronic hepatitis B (HBV) infection.

128 and cirrhosis most commonly associated with chronic hepatitis B (HBV) or hepatitis C (HCV) infection

129 e the effectiveness of current therapies for chronic hepatitis B in clinical practice, given the ther

130 advances have been made in the treatment of chronic hepatitis B in the past decade.

131 s to improve ascertainment and management of chronic hepatitis B in the region.

132 Approved treatments for chronic hepatitis B include 2 formulations of interferon

133 Current guidelines for treatment of chronic hepatitis B include hepatitis B e antigen (HBeAg

134 Chronic hepatitis B infection (HBV) is major cause of mo

135 Chronic hepatitis B infection affects >300 million peopl

136 Eighty-one patients (39.3%) had chronic hepatitis B infection and 23 patients (11.2%) ha

137 among a national cohort of US veterans with chronic hepatitis B infection and examine risk factors f

138 Chronic hepatitis B infection can lead to liver failure,

139 Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B infection has a presentation and cli

140 eatment did not improve clinical outcomes of chronic hepatitis B infection, but the trials were under

141 ope for treating adolescents and adults with chronic hepatitis B infection.

142 out optimal antiviral therapy in adults with chronic hepatitis B infection.

143 HBV-associated disease and for treatment of chronic hepatitis B infection.

144 ation useful for management of patients with chronic hepatitis B infection.

145 In chronic hepatitis B, inflammation is less pronounced in

146 Current approaches to treatment for chronic hepatitis B involve suppression of hepatitis B v

147 Chronic hepatitis B is a serious liver disease and puts

148 Chronic hepatitis B is caused by persistent infection wi

149 One major challenge in the treatment of chronic hepatitis B is to maintain long-term viral suppr

150 ablish a persistent infection in people with chronic hepatitis B, leading to accelerated progression

151 ned the long-term outcome of 265 consecutive chronic hepatitis B liver transplant recipients treated

152 ompare the costs and outcomes of 2 different chronic hepatitis B management strategies.

153 he introduction of these novel compounds for chronic hepatitis B necessitates a standardized appraisa

154 l chronic inflammatory liver diseases, e.g., chronic hepatitis B or C viral infection and steatohepat

155 dle-aged and elderly participants who had no chronic hepatitis B or C virus infection and received he

156 symptoms), and without known HIV infection, chronic hepatitis B or C virus infection, or any conditi

157 symptoms), and without known HIV infection, chronic hepatitis B or C virus infection, or any conditi

158 responses to these viruses in patients with chronic hepatitis B or C, and tailoring the dose of CD13

159 superinfection and sequelae in patients with chronic hepatitis B or C.

160 rom patients with acute hepatitis B, but not chronic hepatitis B or controls, hepatocytes expressed A

161 ff-treatment nucleos(t)ide analogues (NA) in chronic hepatitis B patients (CHB) is unclear.

162 atitis B virus (HBV)-infected hepatocytes of chronic hepatitis B patients and recognize core (HBc18-2

163 rate of drug resistance in nucleoside-naive chronic hepatitis B patients but it is not as effective

164 umerically and functionally impaired pDCs of chronic hepatitis B patients demonstrated reduced PI3K-P

165 Among 2338 chronic hepatitis B patients followed during 2006-2013 i

166 hepatocellular carcinoma (HCC) incidence in chronic hepatitis B patients under long-term therapy wit

167 Chronic hepatitis B patients with high viral loads are a

168 lone without hepatitis B immune globulin for chronic hepatitis B patients with preexisting lamivudine

169 Fifty-seven consecutive chronic hepatitis B patients with preexisting rt204 LAM-

170 cohort study included 1,951 adult Caucasian chronic hepatitis B patients without HCC at baseline who

171 Among 1635 chronic hepatitis B patients, 978 (59.8%) were immune or

172 eyond year 5 of ETV/TDF therapy in Caucasian chronic hepatitis B patients, particularly in those with

173 i-fibrotic activity compared with those from chronic hepatitis B patients, which were mainly mediated

174 They may be used for clinical management of chronic hepatitis B patients.

175 We performed a cohort study of 290 chronic hepatitis B patients: 145 patients treated with

176 ersons vaccinated in infancy, an analysis of chronic hepatitis B prevalence in racial and ethnic popu

177 ents have been approved for the treatment of chronic hepatitis B, ranging in virological potency, cli

178 therapy might be developed for patients with chronic hepatitis B, regardless of their HLA type.

179 he majority of persons currently treated for chronic hepatitis B require long-term or lifelong therap

180 with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B respond to treatment with peginterfe

181 -) ) patients and 266 HBeAg(+) patients with chronic hepatitis B (some nucleoside-naive and some lami

182 In patients with chronic hepatitis B, TAF appears to be as effective as T

183 unotherapeutic strategy for the treatment of chronic hepatitis B, the efficiencies were not adequate

184 ha (IFN-alpha) is an approved medication for chronic hepatitis B therapy.

185 of the most important clinical outcomes for chronic hepatitis B treatment trials.

186 Most individuals with chronic hepatitis B viral (HBV) infection acquired the i

187 Chronic hepatitis B viral (HBV) infection remains a sign

188 is a clinical indicator of poor outcome for chronic hepatitis B viral (HBV) infection.

189 Although the mechanisms by which chronic hepatitis B viral infection results in hepatocel

190 jor mechanisms underlying the development of chronic hepatitis B viral infection.

191 The largest increases were from chronic hepatitis B virus (HBV) (+71), liver transplanta

192 Whether chronic hepatitis B virus (HBV) and hepatitis C virus (H

193 Chronic hepatitis B virus (HBV) and hepatitis C virus (H

194 Chronic hepatitis B virus (HBV) and hepatitis C virus (H

195 Chronic hepatitis B virus (HBV) and hepatitis C virus (H

196 gnose and monitor treatment of patients with chronic hepatitis B virus (HBV) and hepatitis C virus (H

197 In patients with chronic hepatitis B virus (HBV) and hepatitis C virus (H

198 epatitis C virus (HCV) and 203 patients with chronic hepatitis B virus (HBV) before antiviral treatme

199 The inflamed liver in chronic hepatitis B virus (HBV) infection (CHB) is chara

200 ntigen-4 (CTLA-4) to CD8 T cell tolerance in chronic hepatitis B virus (HBV) infection (CHB).

201 Chronic hepatitis B virus (HBV) infection affects 240 mi

202 w the strongest genome-wide association with chronic hepatitis B virus (HBV) infection and HBV recove

203 le experience the highest rates of acute and chronic hepatitis B virus (HBV) infection and hepatocell

204 s, on proliferation of LPCs in patients with chronic hepatitis B virus (HBV) infection and in mice.

205 cohort of 203 treatment-naive patients with chronic hepatitis B virus (HBV) infection and tested for

206 compensatory regeneration that occur during chronic hepatitis B virus (HBV) infection are central to

207 d in antiviral treatment-naive patients with chronic hepatitis B virus (HBV) infection but not in tre

208 ference (RNAi)-based therapeutic ARC-520 for chronic hepatitis B virus (HBV) infection consists of a

209 Treatment of chronic hepatitis B virus (HBV) infection could combine

210 Chronic hepatitis B virus (HBV) infection has a complica

211 Chronic hepatitis B virus (HBV) infection has been assoc

212 The development of therapeutic vaccines for chronic hepatitis B virus (HBV) infection has been hampe

213 Through migration, diversity of chronic hepatitis B virus (HBV) infection has changed, a

214 Patients with chronic hepatitis B virus (HBV) infection have a high ri

215 and new knowledge on the natural history of chronic hepatitis B virus (HBV) infection have expanded

216 he two drugs in patients with HBeAg-negative chronic hepatitis B virus (HBV) infection in a non-infer

217 he two drugs in patients with HBeAg-positive chronic hepatitis B virus (HBV) infection in a non-infer

218 Chronic hepatitis B virus (HBV) infection in children pr

219 s) in the HLA-DP region were associated with chronic hepatitis B virus (HBV) infection in Japanese an

220 rs associated with diabetes in patients with chronic hepatitis B virus (HBV) infection in North Ameri

221 The number of persons with chronic hepatitis B virus (HBV) infection in the United

222 Chronic hepatitis B virus (HBV) infection is a common ca

223 Chronic hepatitis B virus (HBV) infection is a global pu

224 Chronic hepatitis B virus (HBV) infection is a global pu

225 Chronic hepatitis B virus (HBV) infection is a major eti

226 Chronic hepatitis B virus (HBV) infection is a major fac

227 Chronic hepatitis B virus (HBV) infection is a major glo

228 Chronic hepatitis B virus (HBV) infection is a major ris

229 Chronic hepatitis B virus (HBV) infection is a major ris

230 Chronic hepatitis B virus (HBV) infection is a major ris

231 Chronic hepatitis B virus (HBV) infection is a major ris

232 Chronic hepatitis B virus (HBV) infection is estimated t

233 Chronic Hepatitis B Virus (HBV) infection is generally n

234 Chronic hepatitis B virus (HBV) infection is linked to d

235 Chronic hepatitis B virus (HBV) infection is partly resp

236 Chronic hepatitis B virus (HBV) infection is prevalent,

237 A hallmark of chronic hepatitis B virus (HBV) infection is the functio

238 s B e antigen (HBeAg)-negative patients with chronic hepatitis B virus (HBV) infection is unknown.

239 Chronic hepatitis B virus (HBV) infection often develop

240 The heterogeneous clinical courses of chronic hepatitis B virus (HBV) infection reflect the co

241 Chronic hepatitis B virus (HBV) infection remains the mo

242 This PCO addresses recommendations for chronic hepatitis B virus (HBV) infection screening in p

243 Vaccine failure with chronic hepatitis B virus (HBV) infection still develops

244 Patients with chronic hepatitis B virus (HBV) infection who develop an

245 Treatment of patients with chronic hepatitis B virus (HBV) infection who have advan

246 ican nations have among the highest rates of chronic hepatitis B virus (HBV) infection worldwide, but

247 Of 2202 patients with chronic hepatitis B virus (HBV) infection, 50% were aged

248 Chronic hepatitis B virus (HBV) infection, a serious pub

249 proved oral nucleoside analogs used to treat chronic hepatitis B virus (HBV) infection, focusing on b

250 and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believ

251 In patients with chronic hepatitis B virus (HBV) infection, persistent ex

252 For mothers with chronic hepatitis B virus (HBV) infection, the Centers f

253 Using a transgenic mouse model of chronic hepatitis B virus (HBV) infection, we evaluated

254 ms that govern distinct clinical phases of a chronic hepatitis B virus (HBV) infection-immune toleran

255 ear from the liver diseases that result from chronic hepatitis B virus (HBV) infection.

256 unomodulatory effect are rarely addressed in chronic hepatitis B virus (HBV) infection.

257 titis B surface Ag (HBsAg) seroconversion in chronic hepatitis B virus (HBV) infection.

258 ot been extensively studied in patients with chronic hepatitis B virus (HBV) infection.

259 ronic hepatic complications in patients with chronic hepatitis B virus (HBV) infection.

260 but no studies have focused on patients with chronic hepatitis B virus (HBV) infection.

261 lular carcinoma (HCC), often associated with chronic hepatitis B virus (HBV) infection.

262 us (WHV) represent the best animal model for chronic hepatitis B virus (HBV) infection.

263 goal to reduce morbidity and mortality from chronic hepatitis B virus (HBV) infection.

264 is critical to reducing the complications of chronic hepatitis B virus (HBV) infection.

265 nce of NHL between patients with and without chronic hepatitis B virus (HBV) infection.

266 and linkage to care can reduce the burden of chronic hepatitis B virus (HBV) infection.

267 nfections and are particularly promising for chronic hepatitis B virus (HBV) infection.

268 Chronic hepatitis B virus (HBV) infections are associate

269 Chronic hepatitis B virus (HBV) infections are associate

270 rn of hepatitis B surface antigen (HBsAg) in chronic hepatitis B virus (HBV) infections of China rema

271 pment of chronic viral infections, including chronic hepatitis B virus (HBV) infections, are not well

272 rsion represents an endpoint of treatment of chronic hepatitis B virus (HBV) infections.

273 CC) are associated with cirrhosis related to chronic hepatitis B virus (HBV) or hepatitis C virus (HC

274 tty liver disease (NAFLD), and children with chronic hepatitis B virus (HBV) or hepatitis C virus (HC

275 ons, strongyloidiasis from most regions, and chronic hepatitis B virus (HBV) particularly in Asian im

276 s and hepatocellular carcinoma (HCC) risk in chronic hepatitis B virus (HBV) patients.

277 ) in low-replicative (HBV DNA <20,000 IU/mL) chronic hepatitis B virus (HBV) patients.

278 ediated disturbance of Mg(2+) homeostasis on chronic hepatitis B virus (HBV)-infected natural killer

279 onse is compatible with acute, resolved, and chronic hepatitis B virus (HBV)infection but might also

280 Chronic hepatitis B virus carriers are at risk of develo

281 European guidelines recommend treatment of chronic hepatitis B virus infection (CHB) with the nucle

282 IL-10 is elevated in patients with chronic hepatitis B virus infection (CHB), but its cellu

283 surface antigen (HBsAg) testing to identify chronic hepatitis B virus infection for foreign-born per

284 Chronic hepatitis B virus infection is a leading cause o

285 s a therapeutic strategy in the treatment of chronic hepatitis B virus infection or other chronic vir

286 Chronic hepatitis B virus infection predicted longer sur

287 A total of 3087 individuals with chronic hepatitis B virus infection were enrolled betwee

288 h liver fibrosis, as were daily alcohol use, chronic hepatitis B virus infection, body mass index gre

289 and Public Health Management of Persons with Chronic Hepatitis B Virus Infection, recommending screen

290 valuated survival rates among women who have chronic hepatitis B virus infection.

291 ases were attributed to alcoholism or active chronic hepatitis B virus infection.

292 No new acute or chronic hepatitis B virus infections were identified.

293 Chronic hepatitis B virus or hepatitis C co-infection wa

294 ression on viral-responding CD8 T cells from chronic hepatitis B virus patients.

295 ne samples from HBeAg-positive patients with chronic hepatitis B were analyzed.

296 HCC can occur in persons with chronic hepatitis B who have lost HBsAg, even in the abs

297 Differences between patients with chronic hepatitis B with HBsAg clearance and nonresponde

298 reactivation after liver transplantation for chronic hepatitis B, with a durable HBsAg seroclearance

299 ferent disease phases of young patients with chronic hepatitis B, with emphasis on the so-called immu

300 Patients were divided into three groups: chronic hepatitis B without cirrhosis; HBV-related cirrh